BioVaxys submits patent application for Pansabeko virus vaccine

Vancouver, British Columbia, October 21, 2021/PRNewswire/ - BioVaxys Technology Corp.

A study recently published in the New England Journal of Medicine ("NEJM")1 evaluated SARS-Cov-1, a coronavirus similar to SARS-CoV-2 but with a higher mortality rate, which broke out In 2003, it is often referred to as the first global epidemic in the 21st century.

BioVaxys plans to use its haptenized viral protein vaccine platform to vaccinate patients who have recovered from a documented new coronavirus infection or have been vaccinated with a new coronavirus vaccine approved by the World Health Organization with dinitrophenyl ("DNP") A novel vaccine composed of a modified SARS-CoV-1 S spike protein, which induces an immune response to all or most of the Sabeco viruses

David Berd, Chief Medical Officer of BioVaxys, said: “Scientists dream of developing a pan-coronavirus vaccine to protect people from any SARS-type respiratory viruses that may mutate and emerge from wild animals in the future

James Passin, CEO of BioVaxys, said: “More than 217 million people have recovered after being diagnosed with COVID-19 ( and 6.

In order to provide greater certainty, BioVaxys makes no explicit or implicit statement about its current ability to treat the new coronavirus

1) N Engl J Med 2021; 385:1401-1406 DOI: 10.

2) Journal of Emerg Infect Dis.

†Boston Public Health Commission, Massachusetts, USA 

, James W.

†Boston Public Health Commission, Massachusetts, USA 

Centers for Disease Control and Prevention, Atlanta, Georgia, USA;

†Boston Public Health Commission, Massachusetts, USA

About BioVaxys Technology Corp.

BioVaxys Technology Corp.

Representative board

Signed "James Passin" 

James Passin, CEO 

+1 646 452 7054

Cautionary statement regarding forward-looking information 

This press release contains certain "forward-looking information" and "forward-looking statements" (collectively referred to as "forward-looking statements") as defined in relevant Canadian and U.

These forward-looking statements reflect the views, opinions and forecasts as of the date of the statement, and are based on certain assumptions and estimates

Unless required by law, the company has no obligation to update relevant forward-looking statements based on changes in opinions, opinions, forecasts or other factors